Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation
1Department of Physiology and Regenerative Medicine, Kindai University Faculty of Medicine, Osakasayama, Japan.
Comprehensive Physiology
|October 27, 2016
Summary
Plasminogen activator inhibitor-1 (PAI-1), an adipokine from visceral fat, disrupts metabolism and vascular health. Elevated PAI-1 levels are linked to insulin resistance, metabolic syndrome, and cardiovascular disease.
Area of Science:
- Endocrinology
- Vascular Biology
- Metabolic Physiology
Background:
- Adipose tissue functions as an endocrine organ, releasing adipokines.
- Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis.
- Visceral fat is a significant source of circulating PAI-1.
Purpose of the Study:
- To explore the role of adipose tissue-derived PAI-1 as a crucial adipokine.
- To investigate the impact of PAI-1 on physiological metabolism and vascular biology.
- To understand PAI-1's involvement in metabolic abnormalities and disease pathogenesis.
Main Methods:
- Review of existing literature on PAI-1 and adipose tissue.
- Analysis of PAI-1's cellular effects independent of fibrinolysis.
- Examination of PAI-1's role in various pathological conditions.
Main Results:
- Adipose-derived PAI-1 negatively affects metabolism and vascular function.
- Elevated PAI-1 levels are associated with insulin resistance and metabolic syndrome.
- PAI-1 contributes to cardiovascular disease, osteoporosis, sarcopenia, NAFLD, and cancer.
Conclusions:
- Adipose tissue-derived PAI-1 is a critical adipokine with broad physiological and pathological implications.
- PAI-1 dysregulation contributes to metabolic syndrome and cardiovascular disease.
- PAI-1 presents potential as a disease activity marker and therapeutic target.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:20The JAK-STAT Signaling Pathway
13.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.6K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:22Formation of the Platelet Plug
10.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.3K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
578
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
578